Evolus (EOLS) Convertible Debt (2020)
Evolus (EOLS) reported Convertible Debt of $40.5 million for Q4 2020, up 0.75% quarter-over-quarter from $40.2 million in Q3 2020.
Evolus (EOLS) Convertible Debt (2020) Analysis & Trends
Evolus has reported Convertible Debt for 1 years, with the latest figure at $40.5 million in Q4 2020.
- For the quarter ending Q4 2020, Convertible Debt changed N/A year-over-year to $40.5 million; the trailing twelve-month figure through Dec 2020 stood at $40.5 million (changed N/A YoY), and the FY2020 full-year result was $40.5 million, changed N/A from the prior year.
- Convertible Debt for Q4 2020 stood at $40.5 million, up from $40.2 million in the prior quarter.
- The five-year high for Convertible Debt was $40.5 million in Q4 2020, with the low at $40.2 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 40.51 Mn |
| Sep 30, 2020 | 40.20 Mn |